Prolonged VEN therapy has been shown to reduce survival dependence of hematological cancers on Bcl-2, thereby promoting the selective survival of VEN-refractory cells [7, 8]. This evidence concerns the gene BCL2 and hematopoietic and lymphoid cell neoplasm.